Lok Chung Chan

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Part of Morningside Group Ltd., Morningside Venture Investments Ltd. is a There is no available country named vg company that provides investment services. The private company is based in Road Town, British Virgin Islands. The company was founded by Gerald Chan.

Council on Foreign Relations, Inc. provides and disseminates ideas on foreign policies to individuals, corporate members, journalists and policy makers. It operates a forum for government officials, students and other interested parties to study and discuss world issues and impact on American foreign policies. The company publishes Foreign Affairs, a magazine that comes out six times a year, along with books and studies by its own scholars. Council on Foreign Relations was founded in 1921 and is headquartered in New York City, NY.

Morningside Group (Morningside Group) is a venture capital and private equity firm founded in 1986 by Lok Chung Chan and Chi Chung Chan. The firm is headquartered in Hong Kong.

The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA.

New York Academy of Sciences is an independent, not-for-profit organization, which engages in the advancement of scientific research, education, and policy. The company was founded in 1817 and is headquartered in New York, NY.

Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

MetaCure (USA), Inc. engages in the development and commercialization of invasive treatment for diabetes. The company was founded by Shlomo Ben-Haim in 2003 and is headquartered in Orangeburg, NY.

Advanced Cell Diagnostics, Inc. operates as a biotechnology company. It specializes in the emerging field of molecular pathology and developing cell- and tissue-based diagnostic tests for personalized medicine. The company was founded by Lou Yuling and Steve Chan in 2006 and is headquartered in Newark, CA.

MatriVAX, Inc. operates as a biotechnology company. It develops technologies for simplified, low-cost production of vaccines against polysaccharide antigens from pathogenic bacteria. The company was founded by Yichen Lu and John Mekalanos in 2007 and is headquartered in Boston, MA.

Synchroneuron, Inc. develops therapies for tardive dyskinesia (TD) and other neuropsychiatric disorders. It offers a novel treatment for movement disorders, utilizing a drug with simultaneous effects on excitatory and inhibitory neurotransmission. The company was founded by Kei-Lai L. Fong, William D. Kerns, Marc R. Cote and Barry S. Fogel in 2011 and is headquartered in Newton, MA.

Insilixa, Inc. develops molecular diagnostic platform. It offers CMOS biochips for microarray technology, qPCR, and DNA sequencing. The company was founded by Arun Manickam and Arjang Hassibi in 2012 and is headquartered in Sunnyvale, CA.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

LumiraDx UK Ltd. is a POC diagnostic company. The firm focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes. It develops and launches platform, which is an integrated system comprised of a small, versatile Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. The company was founded by Ronald Zwanziger, Jerry McAleer and David Scott on September 5, 2014 and is headquartered in George Town, Cayman Islands.

Canopy Education, Inc. engages in the operation of a mentorship, test preparation and college consulting firm. It offers college and elite application programs, college essay assistance, school list creation and subject tutoring services. The company was founded by Zack Perkins, Johan Zhang, Mohan Zhang, and Vinay Bhaskara in 2013 and is headquartered in Cambridge, MA.

Part of Morningside Group Ltd., the private company is a biotechnology firm based in Newton Center, MA. The company provides innovative solutions for drug discovery and development, with a focus on cancer and rare diseases. Morningside Group Ltd. (United States) provides investment services. The company was founded by Gerald Chan.

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA.

Part of Stealth BioTherapeutics Corp., Stealth BioTherapeutics, Inc. develops therapies to treat mitochondrial dysfunctions and age-related diseases. The private company is based in Newton, MA. The company was founded in 2007. Irene P. McCarthy has been the CEO of the company since 2009.

Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020.

Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA.

Natural Polymer International Corp. manufactures and markets pet products. Its services include product development, design and formulation, computer-aided design drawing, production mold and dies, temporary molds and dies, raw material sourcing, injection molding, extrusion, co-extrusion and cold-extrusion, packing, and display design. It products include N-bone, Twistix, and Get Naked. The company was founded by Scott Wang and Lok Chung Chan in 1996 and is headquartered Plano, TX.